Show simple item record

dc.contributor.authorAkay, Aynur Pekcanlar
dc.contributor.authorKaya, Gamze Capa
dc.contributor.authorKose, Samet
dc.contributor.authorYazicioglu, Cigdem Eresen
dc.contributor.authorErkuran, Handan Ozek
dc.contributor.authorGuney, Sevay Alsen
dc.contributor.authorRohde, Luis Augusto
dc.date.accessioned2020-02-16T17:35:12Z
dc.date.available2020-02-16T17:35:12Z
dc.date.issued2018
dc.identifier.issn0278-5846
dc.identifier.issn1878-4216
dc.identifier.urihttps://dx.doi.org/10.1016/j.pnpbp.2018.04.008
dc.identifier.urihttps://hdl.handle.net/20.500.11782/1530
dc.descriptionWOS: 000436416800034en_US
dc.description#REF!en_US
dc.description.abstractAim: To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-(99m)] TRODAT-1SPECT in a sample of treatment-naive adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). In addition, to assess whether risk alleles (homozygosity for 10-repeat allele at the DAT1 gene were associated with alterations in striatal DAT availability. Methods: Twenty adolescents with ADHD underwent brain single-photon emission computed tomography (SPECT) scans with [Tc-(99m)] TRODAT-1 at baseline and two months after starting OROS-MPH treatment with dosages up to 1 mg/kg/day. Severity of illness was estimated using the Clinical Global Impression Scale (CGI-S) and DuPaul ADHD Rating Scale-Clinician version (ARS) before treatment,1 month and 2 months after initiating OROS-MPH treatment. Results: Decreased DAT availability was found in both the right caudate (pretreatment DAT binding: 224.76 +/- 33.77, post-treatment DAT binding: 208.86 +/- 28.75, p = 0.02) and right putamen (pre-treatment DAT binding: 314.41 +/- 55.24, post-treatment DAT binding: 285.66 +/- 39.20, p = 0.05) in adolescents with ADHD receiving OROS-MPH treatment. Adolescents with ADHD who showed a robust response to OROS-MPH (n = 7) had significantly greater reduction of DAT density in the right putamen than adolescents who showed less robust response to OROS-MPH (n = 13) (p = 0.02). However, between-group differences by treatment responses were not related with DAT density in the right caudate. Risk alleles (homozygosity for the 10-repeat allele of DAT1 gene) in the DAT1 gene were not associated with alterations in striatal DAT availability. Conclusion: Two months of OROS-MPH treatment decreased DAT availability in both the right caudate and putamen. Adolescents with ADHD who showed a robust response to OROS-MPH had greater reduction of DAT density in the right putamen. However,our findings did not support an association between homozygosity for a 10-repeat allele in the DAT1 gene and DAT density, assessedusing[Tc-(99m)] TRODAT-1SPECT.en_US
dc.description.sponsorshipDokuz Eylul University Research CommitteeDokuz Eylul University [2008132]; Fogarty MH/DD program; Institute of Nuclear Energy Research (INER-Taipei, Taiwan)en_US
dc.description.sponsorshipThis study was partially supported by Dokuz Eylul University Research Committee (2008132), Fogarty MH/DD program and the Institute of Nuclear Energy Research (INER-Taipei, Taiwan).en_US
dc.language.isoengen_US
dc.publisherPERGAMON-ELSEVIER SCIENCE LTDen_US
dc.relation.isversionof10.1016/j.pnpbp.2018.04.008en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectADHDen_US
dc.subjectDAT1 geneen_US
dc.subject[Tc-(99m)] TRODAT-1 SPECTen_US
dc.subjectOROS-methylphenidateen_US
dc.titleGenetic imaging study with [Tc-(99m)] TRODAT-1 SPECT in adolescents with ADHD using OROS-methylphenidateen_US
dc.typearticleen_US
dc.relation.journalPROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRYen_US
dc.contributor.departmentHKÜ, 0- Bölüm Yoken_US
dc.identifier.volume86en_US
dc.identifier.startpage294en_US
dc.identifier.endpage300en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record